453 results about "Bicarbonate" patented technology

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention discloses polyether-ether-ketone resin with adjustable molecular weight distribution as well as a synthesis method and application of the polyether-ether-ketone resin. The synthesis method comprises the following steps: preparing polyether-ether-ketone resin in the presence of carbonate and / or bicarbonate of alkali metal; wherein the carbonate and / or bicarbonate of the alkali metal comprises sodium carbonate and potassium carbonate, and the sodium carbonate has gradient particle size distribution. According to the invention, sodium carbonate with specific particle size distribution is used to regulate and control the reaction rate to be stable and continuous, so that the molecular weight distribution of the polymer presents a narrower distribution form. Therefore, the molecular structure is uniform, the molecular form is uniform, the physical and chemical properties, including mechanical strength, thermal stability and chemical stability, of the material can be improved, and particularly, the thermal stability of the material is improved most remarkably.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The present invention relates to a pharmaceutical composition comprising a weak acid drug, with the use of a bicarbonate salt to achieve a high incorporation of the drug into the liposome and a better therapeutic efficacy. Also disclosed is a method for treating a respiratory disease using the pharmaceutical composition disclosed herein.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention relates to the technical field of fireproof materials, and discloses a flame retardant for fireproof paint and a preparation method of the flame retardant. The flame retardant is prepared from modified aluminum polyphosphate, a borate-phosphate composite acid source, a silica modified carbon forming agent, chitosan modified nano carbon, melamine cyanurate, bicarbonate, graphene oxide, nano titanium dioxide and an interface reinforcing agent. Through the multi-stage catalysis of the composite acid source, the efficient charring of the modified charring agent, the multi-stage gas source release and the synergistic effect of the nano additive, a compact and uniform expansion layer is formed, and the high-temperature stability, the heat insulation performance and the thickness retention rate in a dynamic environment of the expansion layer are remarkably improved. According to the preparation method, by optimizing the steps of mixing, dispersing, drying and curing the components, the high-efficiency exertion of the performance of the flame retardant is ensured. The flame retardant is widely applicable to fireproof coatings for buildings, steel structures, wood and the like, has the characteristics of high expansion efficiency, lasting heat insulation and excellent mechanical properties, and effectively overcomes the defects in the prior art.

The additive 50 is used alone as a tablet or capsule, or together with a base product 54, to produce an enhancing product 52 that provides a health benefit 34 to a person 20 ingesting or using the additive 50, the additive 50 including an enzyme that stimulates the naturally occurring in the human body. The additive 50 has one or more hydrogenated substances 58, such as erythritol 58a, xylitol 58b, hydrogenated dihydromyricetin 58c and / or quercetin dihydrate 58d, and a flavonoid dihydromyricetin 14a. The flavonoid 14 may be extracted from Ampelopsis grossedentata plant 17 and / or a plant 16 selected from the genus Hovenia (e.g., Japanese raisin tree). The additive may also have one or more solvents 60, such as a bicarbonate compound 60a or an alcohol solvent 60b, a pH balanced acid 62, and / or a preservative 64. The base product 54 may be a liquid 66, a solid 68, a powder 70, a chew 72, a medicament 74, a cosmetic 76, or an emulsion or other coating product 78. The reinforced product 52 is a base product 54 reinforced by an additive.

Disclosed herein are dosage forms comprising a combination of: 1) an active pharmaceutical ingredient (API), 2) a cyclodextrin, and 3) a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the drug for the treatment of conditions such as pain.

The invention relates to the technical field of gene engineering and recombinase catalysis engineering, in particular to a recombinant strain for expressing phenolic acid decarboxylase as well as a construction method and application of the recombinant strain. According to the invention, a recombinant strain for expressing the phenolic acid decarboxylase PADCs is constructed by heterologous expression of a coding gene PADCs of the phenolic acid decarboxylase. The enzyme liquid of the recombinant strain for expressing the phenolic acid decarboxylase has remarkable catalytic performance, p-coumaric acid can be used as a substrate, the recombinant strain is used for inducing expression, the purified enzyme liquid is used for catalyzing decarboxylation reaction of p-coumaric acid, and p-hydroxystyrene is synthesized; meanwhile, the phenolic acid decarboxylase PADCs has a wide substrate spectrum, the 4-vinylphenol compound can be used as a substrate, bicarbonate is used as a carboxyl source, the freeze-dried whole cell of the recombinant strain is utilized to catalyze the 4-vinylphenol compound to carry out regioselective beta-carboxylation reaction, a series of phenolic acids with biological activity are synthesized by an enzymic method, and meanwhile CO2 is immobilized; and a huge application potential is provided for the utilization of CO2.

This application relates to the field of ceramsite, and specifically discloses a process method for producing coal gangue ceramsite by microwave drying, which includes the following steps: Coal gangue pretreatment: Granulate coal gangue powder and bicarbonate under the action of a wetting agent to form green coal gangue balls, and dry the green coal gangue balls with microwave; 90 - 100 parts of coal gangue powder, 1 - 4 parts of bicarbonate, 3 - 8 parts of wetting agent; The wetting agent includes raw materials in the following weight parts: 1 - 3 parts of polyvinyl alcohol, 1.5 - 4 parts of sodium carboxymethylcellulose, 0.5 - 1 part of surfactant; Coal gangue ceramsite preparation: After pyrolysis, decarbonization, sintering, and cooling of the dried green coal gangue balls, ceramsite is formed; Pyrolysis includes: Gradient oxygen-controlled pyrolysis of the dried green coal gangue balls, the pyrolysis temperature is 250 - 450 °C, and at the same time, air flow is intermittently introduced to impact the material layer. This method can significantly reduce the bursting rate of ceramsite, the surface of the ceramsite has no cracks, the strength is high, and the product quality is excellent.

The invention relates to the field of gene engineering, in particular to a phenolic acid decarboxylase mutant and application thereof. According to the invention, tryptophan at the 30th site of phenolic acid decarboxylase PADCs from Clostridium sp.DSM 8431 is mutated into leucine, and tyrosine at the 136th site of the phenolic acid decarboxylase PADCs is mutated into tryptophan, so that the phenolic acid decarboxylase mutant is obtained. The phenolic acid decarboxylase mutant can catalyze decarboxylation reaction of p-coumaric acid to synthesize p-hydroxystyrene; and hydrocarbonate can also be used as a carboxyl source to catalyze carboxylation reaction of p-hydroxystyrene to synthesize p-coumaric acid. The phenolic acid decarboxylase PADCs has the enzyme activity characteristics of excellent temperature stability and acetonitrile stability, still retains more than 80% of decarboxylase activity after being incubated for 2 hours at 55 DEG C, still retains about 36% of decarboxylase activity after being incubated for 2 hours in acetonitrile with the volume fraction of 50%, can remarkably improve the yield of p-coumaric acid, can reach 13.05 mM when the substrate concentration is 80 mM, and is improved by 74% compared with original phenolic acid decarboxylase PADCs; the method has a wide industrial application prospect and CO2 fixation potential.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

A process for the production of carbon monoxide is described. The process involves the electrochemical desorption of carbon dioxide and oxygen from a solution containing a metal bicarbonate and the formation of carbon monoxide from the carbon dioxide. The carbon monoxide produced can be used in a process for the formation of syngas.

The invention relates to a preparation method of high-purity cesium carbonate, which comprises the following steps: by taking pollucite as a raw material, leaching with sulfuric acid, cooling and crystallizing to obtain crude cesium alum, recrystallizing to obtain high-purity cesium alum, adding at least one of cesium salt or cesium solution of which the cesium molar weight is greater than the aluminum molar weight in the production process in the recrystallization process, removing aluminum, converting, purifying and removing impurities, thereby obtaining the high-purity cesium carbonate. And carrying out evaporation concentration and carbonization crystallization to obtain high-purity cesium bicarbonate, and finally drying and decomposing to obtain a high-purity cesium carbonate product. Compared with a conventional method for preparing cesium carbonate through extracting cesium from pollucite and a conventional method for preparing high-purity cesium carbonate through an extraction method, the method has the advantages that the product purity is greatly improved, the content of cesium carbonate is larger than or equal to 99.999% wt in terms of Cs2CO3, the total amount of impurities including Li, Na, K, Rb, Ca, Mg, Al, Fe, SiO2 and heavy metal (in terms of Pb) is smaller than or equal to 0.001% wt, and especially the content of the same-main-group impurity Rb is smaller than or equal to 0.0001% wt.

The invention belongs to the field of water pollution treatment, and particularly relates to a method for degrading chlorophenol organic pollutants in water by activating persulfate with a cobalt-cerium dioxide monatomic catalyst in the presence of bicarbonate radicals. According to the invention, cerium nitrate hexahydrate is calcined in a muffle furnace to obtain cerium dioxide. A catalyst precursor is prepared by a traditional isovolumetric impregnation method. The prepared catalyst precursor is annealed at different temperatures to obtain a series of catalysts, the catalytic performance of Co1-CeO2-700 is optimal, and the Co1-CeO2-700 has more excellent catalytic performance in the presence of bicarbonate radicals. The preparation method provided by the invention has the advantages of simple steps, convenience in operation, quick effect of treating chlorophenol, high product yield and low cost, and has good economic value and social benefit. The prepared monatomic catalyst has the advantages of being high in atom utilization rate, good in stability, excellent in catalytic effect and the like, and is expected to become a key technology for solving actual water environment organic pollution.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.

The invention provides a low-energy-consumption preparation process of tetramethylammonium bicarbonate, and relates to the technical field of chemical synthesis. The preparation process comprises the following steps: inputting trimethylamine, dimethyl carbonate and a solvent methanol into a reactive distillation tower, carrying out a quaternization reaction to generate methyl carbonate tetramethylammonium, and carrying out a hydrolysis reaction on a first liquid phase obtained by rectification and water vapor to generate TMAB; the reacted material is input into a methanol removal tower for rectification, an obtained second gas phase is heated and pressurized, one part of the second gas phase is input into a subsequent methanol recovery tower, the other part of the second gas phase exchanges heat with water to generate steam, the steam is input into a tower kettle of the methanol removal tower, and high-purity methanol is extracted from the side of the methanol recovery tower. The number of reaction equipment is reduced, and the energy utilization rate is increased; the steam grade is improved by utilizing a heat pump technology, and steam latent heat is integrated between the methanol removal tower and the methanol recovery tower through thermal coupling, so that the overall process energy consumption is remarkably reduced while the product quality is ensured.

The invention discloses a preparation method of polyether-ether-ketone. The preparation method of the polyether-ether-ketone comprises the step of preparing the polyether-ether-ketone in the presence of carbonate and / or bicarbonate of alkali metal, wherein the D90 of the carbonate and / or bicarbonate of the alkali metal is less than 45 [mu] m. Under the condition of reduced pressure operation, when carbonate and / or bicarbonate of alkali metal with D90 smaller than 45 microns are / is used for preparing polyether-ether-ketone, polyether-ether-ketone with properties (such as color, mechanical property and the like) equivalent to those of a conventional process can be obtained, and the gel content is lower.

The invention belongs to the field of bioengineering, and discloses construction of anti-micro-nano bubble escherichia coli and application of the anti-micro-nano bubble escherichia coli in efficient carbon sequestration synthesis of succinic acid. Escherichia coli for producing succinic acid is used as a starting strain, amyloid fibrin (Curli) is amplified and constructed to form an overexpression plasmid of a key gene CsgA, and the starting strain is introduced to obtain an overexpression strain. According to the constructed micro-nano bubble resisting escherichia coli, CO2 micro-nano bubbles serve as the only CO2 donor, no carbonate or bicarbonate needs to be supplemented in the anaerobic fermentation process, cells have excellent resistance to the CO2 micro-nano bubbles, growth and metabolism of the cells are not remarkably inhibited, good succinic acid production performance is kept, and the method is suitable for industrial production. The introduction of CsgA greatly improves the actual utilization efficiency of CO2 gas by thalli, is beneficial to reducing the production cost of succinic acid and improving the environmental benefits of succinic acid, and has wide social and economic values.

A sprayable hydrogel for wound healing caused by bacterial infection and a preparation method thereof, comprising the steps of preparing g-C3N4 nanosheets with melamine as a precursor, and then in-situ reducing HAuCl4·3H2O on the g-C3N4 nanosheets to prepare AuNPs-C3N4 nanozymes; preparing oxidized hyaluronic acid by a sodium periodate oxidation method; incubating the AuNPs-C3N4 nanozyme solution with a glucose solution and then adding a Mn-containing 2+ The manganese salt solution and bicarbonate solution were then mixed with the oxidized hyaluronic acid solution to obtain a dispersion, and the dispersion was sprayed with the carboxymethyl chitosan solution to produce the AuNPs-C3N4 / Glu / Mn 2+ @Carboxymethyl chitosan-OHA hydrogel. The preparation process of this method is simple, and the prepared hydrogel has excellent in vitro antibacterial efficiency, good biocompatibility and bacterial adsorption, which can effectively remove bacteria from wound infection sites and promote wound healing.

Disclosed herein are compositions comprising an NSAID such as meloxicam and / or rizatriptan in combination with a cyclodextrin and / or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.